Filing Details

Accession Number:
0001209191-20-002650
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-08 21:12:38
Reporting Period:
2020-01-06
Accepted Time:
2020-01-08 21:12:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921299 Fibrogen Inc FGEN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1775295 Christine Chung C/O Fibrogen, Inc.
409 Illinois St.
San Francisco CA 94158
Svp, China Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-06 5,625 $25.40 138,269 No 4 M Direct
Common Stock Disposition 2020-01-06 5,625 $42.98 132,644 No 4 S Direct
Common Stock Acquisiton 2020-01-07 5,625 $25.40 138,269 No 4 M Direct
Common Stock Disposition 2020-01-07 5,625 $42.76 132,644 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-01-06 5,625 $0.00 5,625 $25.40
Common Stock Stock Option (Right to Buy) Disposition 2020-01-07 5,625 $0.00 5,625 $25.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
59,339 2027-03-08 No 4 M Direct
53,714 2027-03-08 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. The shares were sold at prices ranging from $42.555 to $43.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The shares were sold at prices ranging from $42.49 to $43.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. Twenty-five percent of the shares subject to the option vested on March 1, 2018, and the remainder vested in equal amounts quarterly thereafter for the following three years.